13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
166 檔
31.0%
During the Q2 2024 filing period, Bellevue Group AG (CIK: 0001674546) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $4.8B across 166 reported positions.
During Q2 2024, Bellevue Group AG's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 6.40% | -1.63% | -0.47% | |
| 2 | ARGX | Argenx Se - Adr | Stock-Healthcare | 4.83% | +0.44% | -14.69% | |
| 3 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.52% | -1.20% | -11.26% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.25% | +0.08% | -7.65% | |
| 5 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 3.90% | -1.01% | -20.86% | |
| 6 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 3.63% | -1.84% | +0.17% | |
| 7 | BSX | Boston Scientific CORP | Stock-Healthcare | 3.22% | -1.39% | -18.39% | |
| 8 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.17% | +0.56% | -0.88% | |
| 9 | SYK | Stryker CORP | Stock-Healthcare | 3.02% | +0.08% | +21.50% | |
| 10 | MRNA | Moderna Inc | Stock-Healthcare | 3.02% | — | -8.61% | |
| 11 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 2.75% | — | -12.35% | |
| 12 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.72% | — | -3.16% | |
| 13 | ABT | Abbott Laboratories | Stock-Healthcare | 2.71% | -1.00% | +11.99% | |
| 14 | DXCM | Dexcom Inc | Stock-Healthcare | 2.34% | -0.01% | +3.89% | |
| 15 | INCY | Incyte CORP | Stock-Healthcare | 2.12% | — | +0.01% | |
| 16 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.89% | -0.19% | +14.26% | |
| 17 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.79% | +0.03% | +6.26% | |
| 18 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.70% | +0.35% | +38.30% | |
| 19 | PODD | Insulet CORP | Stock-Healthcare | 1.43% | -0.41% | +48.19% | |
| 20 | BDX | Becton Dickinson And Co | Stock-Healthcare | 1.32% | -0.11% | -16.45% | |
| 21 | MDT | Medtronic plc | Stock-Healthcare | 1.28% | -0.33% | -0.52% | |
| 22 | BHVN | Biohaven Ltd. | Stock-Other | 1.15% | — | +77.47% | |
| 23 | INSM | Insmed Inc | Stock-Healthcare | 1.11% | +3.09% | -52.30% | |
| 24 | ARVN | Arvinas Inc | Stock-Other | 1.03% | — | — | |
| 25 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.01% | — | -24.05% | |
| 26 | CDNA | Caredx Inc | Stock-Other | 0.99% | — | -0.54% | |
| 27 | ELV | Elevance Health Inc | Stock-Healthcare | 0.89% | +0.09% | +2.98% | |
| 28 | PEN | Penumbra Inc | Stock-Healthcare | 0.82% | -0.10% | EXIT | |
| 29 | EXK | Exact Sciences CORP | Stock-Materials | 0.80% | — | +1.79% | |
| 30 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.79% | -0.10% | +59.13% | |
| 31 | SG7 | Sage Therapeutics Inc | Stock-Other | 0.79% | — | -0.02% | |
| 32 | CRL | Charles River Laboratories | Stock-Healthcare | 0.78% | — | +1.31% | |
| 33 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 0.74% | -0.51% | — | |
| 34 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.73% | +0.01% | -14.30% | |
| 35 | BIO | Bio-rad Laboratories-a | Stock-Healthcare | 0.69% | — | -0.87% | |
| 36 | MGNX | Macrogenics Inc | Stock-Other | 0.69% | — | -0.24% | |
| 37 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 0.68% | — | -24.65% | |
| 38 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.68% | +0.59% | +7.60% | |
| 39 | EPIEUR | Essa Pharma Inc | Stock-Other | 0.67% | — | — | |
| 40 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.66% | -0.06% | -24.84% | |
| 41 | CI | THE Cigna Group | Stock-Healthcare | 0.66% | -0.23% | +54.55% | |
| 42 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.66% | -0.37% | +1.72% | |
| 43 | EXEL | Exelixis Inc | Stock-Healthcare | 0.66% | — | -5.25% | |
| 44 | SRPT | Sarepta Therapeutics Inc | Stock-Healthcare | 0.65% | — | +0.32% | |
| 45 | BDTX | Black Diamond Therapeutics I | Stock-Other | 0.64% | — | — | |
| 46 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.64% | -0.24% | -23.42% | |
| 47 | OPCH | Option Care Health Inc | Stock-Healthcare | 0.64% | — | -24.12% | |
| 48 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.64% | -0.15% | +18.76% | |
| 49 | ALGN | Align Technology Inc | Stock-Healthcare | 0.56% | -0.07% | -7.05% | |
| 50 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.56% | -0.16% | — |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 166 disclosed positions in Q2 2024.
During Q2 2024, Bellevue Group AG's top holdings by market value included IONS (6.4%)、ARGX (4.8%)、VRTX (4.5%). The largest single position, IONS, represented 6.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IONS, ARGX, VRTX) accounted for 31.0% of total reported equity market value during Q2 2024.
In Q2 2024, Bellevue Group AG made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.